vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and ATRenew Inc. (RERE). Click either name above to swap in a different company.
Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $43.2M, roughly 1.0× ATRenew Inc.). ATRenew Inc. runs the higher net margin — 16.9% vs -23.3%, a 40.2% gap on every dollar of revenue.
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
ATRenew Inc.REREEarnings & Financial Report
ATRenew Inc. operates a leading pre-owned consumer electronics transaction and servicing ecosystem primarily in China. Its core services include end-to-end device recycling, professional quality inspection, certified refurbishment, and resale of smartphones, laptops, tablets and other digital products, serving both individual consumers and enterprise clients across domestic and select Southeast Asian markets.
AMRN vs RERE — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2023
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $43.2M |
| Net Profit | $-10.5M | $7.3M |
| Gross Margin | — | — |
| Operating Margin | 35.5% | — |
| Net Margin | -23.3% | 16.9% |
| Revenue YoY | 7.0% | — |
| Net Profit YoY | 33.0% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | — | ||
| Q4 25 | $49.2M | — | ||
| Q3 25 | $49.7M | — | ||
| Q2 25 | $72.7M | — | ||
| Q1 25 | $42.0M | — | ||
| Q4 24 | $62.3M | — | ||
| Q3 24 | $42.3M | — | ||
| Q2 24 | $67.5M | — |
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-7.7M | — | ||
| Q2 25 | $-14.1M | — | ||
| Q1 25 | $-15.7M | — | ||
| Q4 24 | $-48.6M | — | ||
| Q3 24 | $-25.1M | — | ||
| Q2 24 | $1.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | — | ||
| Q3 25 | -22.4% | — | ||
| Q2 25 | -22.0% | — | ||
| Q1 25 | -39.9% | — | ||
| Q4 24 | -84.3% | — | ||
| Q3 24 | -59.5% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | — | ||
| Q3 25 | -15.6% | — | ||
| Q2 25 | -19.4% | — | ||
| Q1 25 | -37.4% | — | ||
| Q4 24 | -78.0% | — | ||
| Q3 24 | -59.4% | — | ||
| Q2 24 | 2.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | — | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $-0.03 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $-0.12 | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | $228.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $557.1M |
| Total Assets | $645.8M | $722.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | — | ||
| Q3 25 | $286.6M | — | ||
| Q2 25 | $298.7M | — | ||
| Q1 25 | $281.8M | — | ||
| Q4 24 | $294.2M | — | ||
| Q3 24 | $305.7M | — | ||
| Q2 24 | $306.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | — | ||
| Q3 25 | $458.9M | — | ||
| Q2 25 | $464.9M | — | ||
| Q1 25 | $473.7M | — | ||
| Q4 24 | $486.2M | — | ||
| Q3 24 | $531.4M | — | ||
| Q2 24 | $551.9M | — |
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | — | ||
| Q3 25 | $659.8M | — | ||
| Q2 25 | $670.1M | — | ||
| Q1 25 | $655.7M | — | ||
| Q4 24 | $685.3M | — | ||
| Q3 24 | $750.6M | — | ||
| Q2 24 | $799.9M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
RERE
Segment breakdown not available.
